NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

A Study of JAB-21822 in Advanced or Metastatic NSCLC With KRAS p.G12C and STK11 Co-mutation and Wild-type KEAP1

RecruitingPhase 1, Phase 2

Sponsor: Allist Pharmaceuticals, Inc.

Conditions: Non-small Cell Lung Cancer

Interventions: JAB 21822

Countries: China

Evaluate the safety and tolerability, drug levels, and clinical activity of JAB-21822 in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors with KRAS p.G12C mutation and a serine/threonine kinase 11 (STK11) co-mutation.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

1. Pathologically documented, locally-advanced or metastatic NSCLC with KRAS p.G12C mutation identified through molecular testing.
2. STK11 co-mutation and KEAP1 Wild-Type (local confirmation)
3. Treatment naïve or have received at least 1 prior standard therapy for advanced NSCLC
4. ECOG 0-1

Exclusion Criteria:

1. Has CNS metastases or carcinomatous meningitis, except treated CNS metastases with no evidence of radiographic progression or hemorrhage for at least 28 days
2. Any severe and/or uncontrolled medical conditions
3. Active infection requiring systemic treatment within 7 days
4. Therapeutic radiation therapy within 3 weeks of study day 1

Locations (21)

Beijing, Beijing Municipality, China
Beijing, Beijing Municipality, China
Beijing, Beijing Municipality, China
Beijing, Beijing Municipality, China
Beijing, Beijing Municipality, China
Beijing, Beijing Municipality, China
Chongqing, Chongqing Municipality, China
Xiamen, Fujian, China
Shenzhen, Guangdong, China
Nanning, Guangxi, China
Shijiazhuang, Hebei, China
Harbin, Heilongjiang, China
Zhengzhou, Henan, China
Changsha, Hunan, China
Changchun, Jilin, China
Shenyang, Liaoning, China
Shenyang, Liaoning, China
Hohhot, Neimenggu, China
Xi’an, Shanxi, China
Hubei, Wuhan, China
Hangzhou, Zhejiang, China